Abstract: A polypeptide or a pharmaceutically acceptable salt thereof having c-AMP-producing activity is disclosed, the polypeptide being represented by the following general formula:X-Ser-Asp-Gly-Ile-Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr-Arg-Lys-Gln-Met-Ala-Val-L ys-Lys-Tyr-Leu-Y (X-SEQ ID NO:2-Y)wherein X represents any amino acid residue or an acyl group, and Y represents NH.sub.2, OH, Ala-NH.sub.2, Ala-OH, Ala-Ala-NH.sub.2, Ala-Ala-OH, Ala-Ala-Val-NH.sub.2 or Ala-Ala-Val-OH.

Abstract: A method of treating cachexia associated with cancer, infectious diseases, or catabolic disorders which comprises administration of an effective amount of interleukin 2 is disclosed.

Abstract: This invention relates to an assay for fibrin polymers for use in the diagnosis of patients at risk of thrombosis and in monitoring the effects of treatment in such patients. More particularly, the present invention relates to an assay for soluble crosslinked fibrin polymers in patent samples involving the in vitro treatment of the sample with a proteolytic enzyme such as t-PA which generates the D-dimer fragment of soluble fibrin polymers. The amount of D-dimer formed is determined by an immunoassay specific for D-dimer. The measurement of D-dimer is thus a useful reflection of the hypercoagulability state and the test may be useful for assessing pre-thrombotic or thrombotic disorders such as myocardial infarction, pulmonary embolism and deep vein thrombosis, as well as for soluble fibrin formation in neoplastic, immune, inflammatory states, or other pathologic conditions, and for evaluations of therapy such as with anticoagulants that are used to treat these conditions.

Abstract: The invention relates to compounds of the formula I ##STR1## in which A denotes an optionally substituted radical from the series comprising alkyl, acyl, cycloalkyl, aryl and heteroaryl; Cyc represents an optionally substituted heterocyclic carbonyl compound; D represents NH, NCH.sub.3, O or CH.sub.2 ; E represents CHOH, CO, SO or optionally N-substituted C.dbd.NH; F represents O, NH, NCH.sub.3 or a bond; R.sup.4 denotes an optionally substituted radical from the series comprising alkyl, cycloalkyl, aryl and heteroaryl; and R.sup.8 denotes hydrogen or optionally substituted alkyl, to a process for the preparation thereof, and to the use thereof as inhibitors of prolyl hydroxylase.

Abstract: Viscoelastic solution including a buffered solution, 0.01-8% chondroitin sulfate, 0.1-8% hydroxypropyl methylcellulose, pH adjusted to 6.0-8.0 at a osmolality between 200-400 mOsmol/L. The buffered solution can be HEPES buffered minimum essential media (MEM), phosphate buffer saline (PBS), buffered balanced salt solution, or TC199. A cell growth factor or cell growth supplement is included in the solution.

Abstract: Novel polypeptide derivatives, acid-addition salts thereof and complexes thereof, having the activities for inhibiting bone calcium absorption, for lowering the blood level of calcium, as analgesics, for inhibiting secretion of the gastric juice.Pharmaceutical composition can be prepared by formulating, at least one of the novel polypeptide derivatives, acid-addition salts thereof and complexes thereof, together with a proteolytic enzyme inhibitors and/or pharmaceutically acceptable acids.The pharmaceutical composition are quite effective as agents for curing hypercalcemia, for curing Peget's disease, for curing osteoporosis, analgetic agent, anti-ulcerative agent and the like.

Abstract: A cyclosporine metabolite having a molecular weight determined by mass spectrometry of about 1205 and having the following properties: (a) being immunologically distinct from cyclosporine metabolites OL-1, OL-17 and OL-8; (b) being more polar than OL-1 or OL-17 and less polar than OL-8 when eluated from a gradient high performance liquid chromatography; (c) being extractable from bile of test animals which have been administered cyclosporine A; and (d) being substantially free of other cyclosporine metabolites and cyclosporine A, and a physiologically acceptable salt or stereoisomer thereof.

Abstract: Imidazole-containing peptide of the formula: ##STR1## wherein R.sup.1 is a branched alkyl group, a branched alkyloxy group or an aryl-substituted lower alkyloxy group, R.sup.2 and R.sup.4 are the same or different and each is hydrogen atom or a lower alkyl group, R.sup.3 and R.sup.5 are a phenyl-substituted lower alkyl group, R.sup.6 is hydrogen atom or a lower alkoxycarbonyl group, R.sup.7 is hydrogen atom or a nitrogen-containing heterocyclic group-substituted lower alkylthio group, X.sup.1 and X.sup.2 are the same or different and each is ##STR2## A is a lower alkylene group which may be substituted with a substituent selected from the group consisting of a lower alkoxy group, hydroxymethyl group and a group of the formula: ##STR3## and R.sup.8 and R.sup.

Abstract: Peptide derivatives of the Formula IR--Y--Leu--Pro--NH--CH(CH.sub.2 --CH.sub.2 --CH.sub.2 --NH--C(.dbd.NH)--NH.sub.2)--Xin which Y is HN--(CH.sub.2).sub.n --CO with n=1 to 8 or a bond, X is CN, CH.sub.2 OH or CHO and R is a support or a hydrogen atom, a process for the preparation thereof, and the use thereof for affinity chromatography, especially for isolating and purifying proteases, are described.

Abstract: This invention relates to a novel glycoprotein with anticoagulant activity in human urine, a process for its preparation and a pharmaceutical composition comprising the said glycoprotein for the prevention and/or treatment of diseases related to the disorders in the blood coagulation system.

Abstract: A method is disclosed for stimulating a mammal's or avian's immune response, particularly immune-compromised mammals, by administration of IGF-I, alone or in combination with growth hormone. Preferably, the IGF-I is native-sequence, mature human IGF-I.

Abstract: Disclosed is a novel polypeptide whose N-terminus is EAQ and which is composed of 60 amino acids. The polypeptide is produced from human breast cancer cell MCF7, or human gastric cancer cell MKN-45 or KATO-III, which polypeptide has a isoelectric point of 4.

Abstract: New retro-inverso analogs of thymopentin (TP5) and of its tripeptide fragment (TP5.sup.1-3) of general formula (I) ##STR1## are described wherein R is hydrogen or an acyl radical, and R.sup.1 is --OR.sup.2 or ##STR2## wherein R.sup.2 is hydrogen or a hydrocarbyl radical, and the corresponding pharmaceutically acceptable acid- or base-addition salts. A process of preparing the tripeptide fragment of formula I is also described.The new compounds are enzyme-resistant immunomodulatory peptides.

Abstract: A method of treating patients having chronic, severe allergic disorders, such as atopic dermatitis or steroid-dependent asthma, with gamma interferon is disclosed. The method involves treating patients afflicated with atopic dermatitis or steroid-dependent asthma with effective dosages of gamma interferon, which reduces the clinical severity of their disease.

Abstract: Compounds and compositions comprising fragments and synthetic analogs of human thrombospondin are provided together with methods for their use as thrombospondin-like agents.

Abstract: The invention synergimicin derivatives having the general formula: Z--X--R, in which Z is a type A or type B synergimycin radical linked by its reactive carbonyl position, through a branch X, where X is .dbd.N-- or .dbd.N--O--, to a substituted R, where R is a hydrogen atom, an alkyl group, an alkyl-COOH group, an -alkyl-(.alpha.NH.sub.2)COOH group (I), group (II), group (III) or a group (IV), where n is a function of the number of --NH.sub.2 groups present on the coupling protein. Also described are the salts, esters and possibly addition products of pharmaceutically acceptable acids. The invention also concerns a process for preparing these substances, and their use.

Abstract: The invention contemplates a metallopeptide and a method for producing the metallopeptide. The metallopeptide comprises a polypeptide bonded to a metal cation at two coordinating amino acid residues that are aqueous solvent-accessible, said metallopeptide having a secondary structure stabilized by said bonded metal cation.

Abstract: Whey derived from ordinary milk includes a bottom fraction including lactose and minerals, a middle fraction including lower molecular weight proteins, and a top fraction including higher molecular weight proteins. The top whey fraction includes a measurable but low level concentration of immunologically active immunoglobulin plus other pathogen specific antibodies. The whey is ultrafiltered through one or more different process steps to yield a filtered product having a concentration of immunologically active immunoglobulin of at least about seven percent of total solids. The filtered product is periodically tested to verify its activity to a specified microbe. The filtered product is orally administered in a therapeutically effective dose to an animal to treat a disease.

Abstract: The use of agonists or antagonists of Mullerian Inhibiting Substance to suppress or treat respiratory distress syndrom. The treatment can be accomplished by providing an effective amount of the agonist or antagonist to a neonatal or prenatal individual.

Abstract: Trauma-associated sepsis is effectively treated using gamma interferon alone or in combination with an antibiotic.